       Document 0046
 DOCN  M9630046
 TI    Interleukin 12 in combination with anti-interleukin 10 reverses graft
       prolongation after portal venous immunization.
 DT    9603
 AU    Gorczynski RM; Hozumi N; Wolf S; Chen Z; Department of Surgery,
       University of Toronto, Canada.
 SO    Transplantation. 1995 Dec 15;60(11):1337-41. Unique Identifier :
       AIDSLINE MED/96106497
 AB    Portal venous pretransplantation transfusion augments allogeneic skin
       graft survival in mice transplanted across multiple minor
       histocompatibility barriers. We have shown in earlier studies that this
       is correlated with preferential activation for production of type-2
       cytokines (interleukin [IL]-4 and IL-10) and decreased production of
       type-1 cytokines (IL-2 and interferon-gamma). We show that recombinant
       IL-12, in association with anti-IL-10 monoclonal antibody, can reverse
       in vivo the graft prolongation afforded by portal venous immunization
       and the altered cytokine production that follows. These alterations are
       in turn associated with increased expression of messenger RNA for
       interferon-gamma, IL-2, and IL-12 and decreased expression of IL-4,
       IL-10, and IL-13, as determined by non-quantitative polymerase chain
       reaction using cells obtained from lymph nodes draining the graft.
       Recombinant IL-12 in vitro also produces dose-related inhibition of
       activation for production of type-2 cytokines.
 DE    Animal  Cytokines/GENETICS/*METABOLISM  Gene Expression  *Graft Survival
       Immunization  Injections, Intravenous  Interleukin-10/*PHYSIOLOGY
       Interleukin-12/*ADMINISTRATION & DOSAGE  Isoantigens/ADMINISTRATION &
       DOSAGE  Lymphocyte Transformation  Mice  Mice, Inbred BALB C  Mice,
       Inbred C3H  Portal Vein  Recombinant Proteins  RNA, Messenger/GENETICS
       Skin Transplantation/*IMMUNOLOGY  Th2 Cells/*IMMUNOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

